GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portola Pharmaceuticals Inc (NAS:PTLA) » Definitions » PB Ratio

Portola Pharmaceuticals (Portola Pharmaceuticals) PB Ratio : 19.64 (As of Apr. 25, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Portola Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Portola Pharmaceuticals's share price is $18.03. Portola Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2020 was $0.92. Hence, Portola Pharmaceuticals's PB Ratio of today is 19.64.

The historical rank and industry rank for Portola Pharmaceuticals's PB Ratio or its related term are showing as below:

PTLA's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.37
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


Portola Pharmaceuticals PB Ratio Historical Data

The historical data trend for Portola Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portola Pharmaceuticals PB Ratio Chart

Portola Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.78 6.66 9.16 14.71 14.33

Portola Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.74 3,014.44 9.80 14.33 7.77

Competitive Comparison of Portola Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Portola Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Portola Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portola Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Portola Pharmaceuticals's PB Ratio falls into.



Portola Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Portola Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2020)
=18.03/0.918
=19.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Portola Pharmaceuticals  (NAS:PTLA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Portola Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Portola Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Portola Pharmaceuticals (Portola Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
270 E. Grand Avenue, South San Francisco, CA, USA, 94080
Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.
Executives
Dennis M Fenton director
John B Moriarty officer: EVP, General Counsel ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Hollings Renton director
David C Stump director
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Jeffrey W Bird director 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Henry Ward Wolff director 6701 KAISER DRIVE, FREMONT CA 94555
J. Scott Garland director, officer: President and CEO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Mardi Dier officer: EVP and CFO C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Rajiv Patni officer: EVP, CMO C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
John T Curnutte officer: EVP R&D PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Charles J Homcy other: Former Director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William Lis director, officer: Chief Executive Officer PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080

Portola Pharmaceuticals (Portola Pharmaceuticals) Headlines

From GuruFocus